RU2004135543A - Орто-замещенные производные бензойной кислоты для лечения резистентности к инсулину - Google Patents
Орто-замещенные производные бензойной кислоты для лечения резистентности к инсулину Download PDFInfo
- Publication number
- RU2004135543A RU2004135543A RU2004135543/04A RU2004135543A RU2004135543A RU 2004135543 A RU2004135543 A RU 2004135543A RU 2004135543/04 A RU2004135543/04 A RU 2004135543/04A RU 2004135543 A RU2004135543 A RU 2004135543A RU 2004135543 A RU2004135543 A RU 2004135543A
- Authority
- RU
- Russia
- Prior art keywords
- benzoic acid
- oxoethoxy
- ethyl
- amino
- phenyl
- Prior art date
Links
- 0 C*1C=CC(C*(*)C(COc2c(C)cc(CC*c(cccc3)c3O)cc2)=O)=CC=C1 Chemical compound C*1C=CC(C*(*)C(COc2c(C)cc(CC*c(cccc3)c3O)cc2)=O)=CC=C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
Claims (10)
1. Соединение формулы I,
где n представляет собой 0, 1 или 2;
R1 представляет собой галогено, С1-4алкильную группу, которая возможно замещена одним или более чем одним атомом фтора, С1-4алкоксильную группу, которая возможно замещена одним или более чем одним атомом фтора, и причем, когда n представляет собой 2, заместители R1 могут быть одинаковыми или разными;
R2 представляет собой неразветвленную С2-7алкильную группу;
R3 представляет собой Н или ОСН3; и
W представляет собой 0 или S;
и его фармацевтически приемлемые соли и пролекарства.
2. Соединение по п.1, где W представляет собой О.
3. Соединение по п.1, где W представляет собой S.
4. Соединение, выбранное из следующего:
2-[2-(4-{2-[этил(2-фторбензил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-[2-(4-{2-[(2,4-дифторбензил)(гептил)-амино]-2-оксоэтокси}-3-метоксифенил)-этокси]-бензойная кислота;
2-[2-(4-{2-[(4-хлорбензил)(этил)-амино]-2-оксоэтокси}-фенил)-этилтио]-бензойная кислота;
2-[2-(4-{2-[(4-хлорбензил)(этил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-[2-(4-{2-[этил(4-трифторметилбензил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-[2-(4-{2-[этил(4-трифторметилбензил)-амино]-2-оксоэтокси}-фенил)-этилтио]-бензойная кислота;
2-{2-[4-(2-{бутил[2-фтор-4-(трифторметил)-бензил]-амино}-2-оксоэтокси)-фенил]-этокси}-бензойная кислота;
2-[2-(4-{2-[(2,4-дифторбензил)(пропил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-[2-(4-{2-[бензил(этил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-{[2-(4-{2-[бензил(этил)-амино]-2-оксоэтокси}-фенил)-этил]-тио}-бензойная кислота;
2-[2-(4-{2-[(4-mpem-бутилбензил)(этил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-[2-(4-{2-[этил-(4-фторбензил)-амино]-2-оксоэтокси}-фенил)-этокси]-бензойная кислота;
2-{[2-(4-{2-[этил-(2-фторбензил)-амино]-2-оксоэтокси}-фенил)-этил]-тио}-бензойная кислота; или
2-{[2-(4-{2-[(2-хлорбензил)(этил)-амино]-2-оксоэтокси}-фенил)-этил]-тио}-бензойная кислота
и его фармацевтически приемлемые соли.
5. Фармацевтический препарат, содержащий соединение по любому из пп.1-4 в смеси с фармацевтически приемлемыми адъювантами, разбавителями и/или носителями.
6. Способ лечения или предотвращения резистентности к инсулину, при котором вводят соединение по любому из пп.1-4 млекопитающему, которое в этом нуждается.
7. Применение соединения по любому из пп.1-4 в изготовлении медикамента для лечения резистентности к инсулину.
9. Соединение формулы II как описано в п.8.
10. Комбинационное лечение, включающее в себя соединение по любому из пп.1-4 в комбинации с другим терапевтическим агентом, который является полезным в лечении нарушений, ассоциированных с развитием и прогрессированием атеросклероза, таких как гипертензия, гиперлипидемия, дислипидемия, диабет и ожирение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201936-2 | 2002-06-20 | ||
SE0201936A SE0201936D0 (sv) | 2002-06-20 | 2002-06-20 | Therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004135543A true RU2004135543A (ru) | 2005-08-10 |
RU2288912C2 RU2288912C2 (ru) | 2006-12-10 |
Family
ID=20288294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004135543/04A RU2288912C2 (ru) | 2002-06-20 | 2003-06-17 | Ортозамещенные производные бензойной кислоты, способ и промежуточные соединения для их получения, фармацевтическая композиция на их основе и применение |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1517679B1 (ru) |
JP (1) | JP2005535618A (ru) |
KR (1) | KR20050014015A (ru) |
CN (1) | CN1307988C (ru) |
AR (1) | AR039714A1 (ru) |
AT (1) | ATE385790T1 (ru) |
AU (1) | AU2003240100B2 (ru) |
BR (1) | BR0311839A (ru) |
CA (1) | CA2490684A1 (ru) |
DE (1) | DE60319082T2 (ru) |
DK (1) | DK1517679T3 (ru) |
ES (1) | ES2299703T3 (ru) |
HK (1) | HK1074779A1 (ru) |
IL (1) | IL165670A0 (ru) |
IS (1) | IS7626A (ru) |
MX (1) | MXPA04012685A (ru) |
NO (1) | NO20045223L (ru) |
NZ (1) | NZ536971A (ru) |
PL (1) | PL375080A1 (ru) |
PT (1) | PT1517679E (ru) |
RU (1) | RU2288912C2 (ru) |
SE (1) | SE0201936D0 (ru) |
TW (1) | TW200407114A (ru) |
UA (1) | UA76627C2 (ru) |
WO (1) | WO2004000294A1 (ru) |
ZA (1) | ZA200409693B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
EP1517883B8 (en) | 2002-06-20 | 2008-05-21 | AstraZeneca AB | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
PL219045B1 (pl) * | 2010-10-16 | 2015-03-31 | Inst Chemii Organicznej Polskiej Akademii Nauk | Nowe estry (acyloksymetylo)akrylamidu, kompozycja farmaceutyczna zawierająca je oraz ich zastosowanie |
US10653681B2 (en) | 2016-03-16 | 2020-05-19 | Recurium Ip Holdings, Llc | Analgesic compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 |
US6509374B2 (en) * | 2000-04-17 | 2003-01-21 | Novo Nordisk A/S | Compounds, their preparation and use |
-
2002
- 2002-06-20 SE SE0201936A patent/SE0201936D0/xx unknown
-
2003
- 2003-06-17 WO PCT/GB2003/002591 patent/WO2004000294A1/en active IP Right Grant
- 2003-06-17 AT AT03732714T patent/ATE385790T1/de not_active IP Right Cessation
- 2003-06-17 EP EP03732714A patent/EP1517679B1/en not_active Expired - Lifetime
- 2003-06-17 CA CA002490684A patent/CA2490684A1/en not_active Abandoned
- 2003-06-17 DK DK03732714T patent/DK1517679T3/da active
- 2003-06-17 AU AU2003240100A patent/AU2003240100B2/en not_active Ceased
- 2003-06-17 DE DE60319082T patent/DE60319082T2/de not_active Expired - Lifetime
- 2003-06-17 NZ NZ536971A patent/NZ536971A/en unknown
- 2003-06-17 RU RU2004135543/04A patent/RU2288912C2/ru not_active IP Right Cessation
- 2003-06-17 KR KR10-2004-7020689A patent/KR20050014015A/ko not_active Application Discontinuation
- 2003-06-17 PT PT03732714T patent/PT1517679E/pt unknown
- 2003-06-17 PL PL03375080A patent/PL375080A1/xx not_active Application Discontinuation
- 2003-06-17 BR BR0311839-8A patent/BR0311839A/pt not_active IP Right Cessation
- 2003-06-17 CN CNB038198533A patent/CN1307988C/zh not_active Expired - Fee Related
- 2003-06-17 MX MXPA04012685A patent/MXPA04012685A/es active IP Right Grant
- 2003-06-17 ES ES03732714T patent/ES2299703T3/es not_active Expired - Lifetime
- 2003-06-17 UA UA20041210012A patent/UA76627C2/uk unknown
- 2003-06-17 JP JP2004515008A patent/JP2005535618A/ja active Pending
- 2003-06-17 TW TW092116410A patent/TW200407114A/zh unknown
- 2003-06-20 AR ARP030102198A patent/AR039714A1/es unknown
-
2004
- 2004-11-29 NO NO20045223A patent/NO20045223L/no not_active Application Discontinuation
- 2004-11-30 ZA ZA200409693A patent/ZA200409693B/en unknown
- 2004-12-09 IL IL16567004A patent/IL165670A0/xx unknown
-
2005
- 2005-01-05 IS IS7626A patent/IS7626A/is unknown
- 2005-08-16 HK HK05107074A patent/HK1074779A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1517679B1 (en) | 2008-02-13 |
PT1517679E (pt) | 2008-04-21 |
DE60319082D1 (de) | 2008-03-27 |
SE0201936D0 (sv) | 2002-06-20 |
EP1517679A1 (en) | 2005-03-30 |
CN1307988C (zh) | 2007-04-04 |
NO20045223L (no) | 2005-03-17 |
NZ536971A (en) | 2006-05-26 |
CA2490684A1 (en) | 2003-12-31 |
AU2003240100A1 (en) | 2004-01-06 |
RU2288912C2 (ru) | 2006-12-10 |
BR0311839A (pt) | 2005-04-05 |
CN1674883A (zh) | 2005-09-28 |
ATE385790T1 (de) | 2008-03-15 |
DE60319082T2 (de) | 2009-01-29 |
MXPA04012685A (es) | 2005-03-23 |
WO2004000294A1 (en) | 2003-12-31 |
JP2005535618A (ja) | 2005-11-24 |
IL165670A0 (en) | 2006-01-15 |
ES2299703T3 (es) | 2008-06-01 |
HK1074779A1 (en) | 2005-11-25 |
AR039714A1 (es) | 2005-03-09 |
ZA200409693B (en) | 2005-10-11 |
KR20050014015A (ko) | 2005-02-05 |
PL375080A1 (en) | 2005-11-14 |
AU2003240100B2 (en) | 2006-06-01 |
UA76627C2 (en) | 2006-08-15 |
DK1517679T3 (da) | 2008-05-19 |
IS7626A (is) | 2005-01-05 |
TW200407114A (en) | 2004-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007502806A5 (ru) | ||
RU2335493C2 (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
RU2006107653A (ru) | Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли | |
JP2006500384A5 (ru) | ||
JP2006501295A5 (ru) | ||
JP2012236838A5 (ru) | ||
JP2002513793A5 (ru) | ||
RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
JP2007523155A5 (ru) | ||
CA2436846A1 (en) | Thioether substituted imidazoquinolines | |
JP2008505171A5 (ru) | ||
JP2005511547A5 (ru) | ||
KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
JP2008530242A5 (ru) | ||
JP2008533063A5 (ru) | ||
RU2004135542A (ru) | Производные бензойной кислоты как модуляторы ppara и ppary | |
RU2019128534A (ru) | Химические соединения для лечения туберкулеза | |
JP2007522178A5 (ru) | ||
CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
JP2007529471A5 (ru) | ||
JP2005532397A5 (ru) | ||
CA2575512A1 (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
RU2005131937A (ru) | Макролидные конъюгаты, с противовоспалительной активностью | |
RU2004135543A (ru) | Орто-замещенные производные бензойной кислоты для лечения резистентности к инсулину | |
JP2008520611A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090618 |